Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Price Performance

AEMD opened at $0.40 on Thursday. The company has a market capitalization of $6.50 million, a PE ratio of -0.26 and a beta of 1.93. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.06. The business has a 50-day moving average of $0.38 and a 200-day moving average of $0.49.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, equities research analysts expect that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

Institutional investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the 4th quarter worth about $186,000. Virtu Financial LLC acquired a new stake in Aethlon Medical in the 4th quarter worth approximately $81,000. Sassicaia Capital Advisers LLC bought a new stake in Aethlon Medical during the fourth quarter worth approximately $31,000. Allegiance Financial Group Advisory Services LLC acquired a new position in Aethlon Medical during the fourth quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $25,000. 1.99% of the stock is currently owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.